Phosphorylated amyloid-beta: the toxic intermediate in alzheimer's disease neurodegeneration

Research output: Contribution to journalReview articlepeer-review

22 Citations (Scopus)


Phosphorylated Amyloid-beta (Abeta) was identified in Alzheimer's disease (AD) brain. Using an anti-sense peptide approach the human cyclin-dependent kinase-1 (CDK-1) was identified as being responsible for Abeta phosphorylation. The phosphorylated Abeta peptide showed increased neurotoxicity and reduced ability to form Congo red-positive fibrils. Mutation of the serine 26 residue and inhibition of Abeta phosphorylation by the CDK-1 inhibitor olomoucine prevented Abeta toxicity, suggesting that the phosphorylated Abeta peptide represents a toxic intermediate. Cannabinoids prevented phosphorylated Abeta toxicity. 

The results from this study suggest that Abeta phosphorylation could play a role in AD pathology and represent a novel therapeutic target.

Original languageEnglish
Pages (from-to)381-402
Number of pages22
JournalSubcellular Biochemistry
Publication statusPublished - 2005
Externally publishedYes


  • Alzheimer Disease/pathology
  • Amyloid beta-Peptides/metabolism
  • Animals
  • Cyclin-Dependent Kinases/antagonists & inhibitors
  • Enzyme Inhibitors/therapeutic use
  • Humans
  • Kinetin
  • Nerve Degeneration/pathology
  • Phosphoproteins/antagonists & inhibitors
  • Phosphorylation
  • Purines/therapeutic use


Dive into the research topics of 'Phosphorylated amyloid-beta: the toxic intermediate in alzheimer's disease neurodegeneration'. Together they form a unique fingerprint.

Cite this